Sexually Dimorphic Development of the Mammalian Reproductive Tract Requires Wnt-7a
Authors
Affiliations
An important feature of mammalian development is the generation of sexually dimorphic reproductive tracts from the Müllerian and Wolffian ducts. In females, Müllerian ducts develop into the oviduct, uterus, cervix and upper vagina, whereas Wolffian ducts regress. In males, testosterone promotes differentiation of Wolffian ducts into the epididymis, vas deferens and seminal vesicle. The Sertoli cells of the testes produce Müllerian-inhibiting substance, which stimulates Müllerian duct regression in males. The receptor for Müllerian-inhibiting substance is expressed by mesenchymal cells underlying the Müllerian duct that are thought to mediate regression of the duct. Mutations that inactivate either Müllerian-inhibiting substance or its receptor allow development of the female reproductive tract in males. These pseudohermaphrodites are frequently infertile because sperm passage is blocked by the presence of the female reproductive system. Here we show that male mice lacking the signalling molecule Wnt-7a fail to undergo regression of the Müllerian duct as a result of the absence of the receptor for Müllerian-inhibiting substance. Wnt7a-deficient females are infertile because of abnormal development of the oviduct and uterus, both of which are Müllerian duct derivatives. Therefore, we propose that signalling by Wnt-7a allows sexually dimorphic development of the Müllerian ducts.
McLamb F, Feng Z, Vu J, Griffin L, Vasquez M, Bozinovic G Mol Neurobiol. 2024; 62(3):2955-2972.
PMID: 39196495 PMC: 11790743. DOI: 10.1007/s12035-024-04427-7.
MAP3K1 regulates female reproductive tract development.
Kimura E, Mongan M, Xiao B, Christianto A, Wang J, Carreira V Dis Model Mech. 2024; 17(3).
PMID: 38501211 PMC: 10985838. DOI: 10.1242/dmm.050669.
Characterization of the human fetal gonad and reproductive tract by single-cell transcriptomics.
Taelman J, Czukiewska S, Moustakas I, Chang Y, Hillenius S, Helm T Dev Cell. 2024; 59(4):529-544.e5.
PMID: 38295793 PMC: 10898717. DOI: 10.1016/j.devcel.2024.01.006.
Lofrano-Porto A, Pereira S, Dauber A, Bloom J, Fontes A, Asimow N J Clin Invest. 2023; 133(23).
PMID: 37847567 PMC: 10688984. DOI: 10.1172/JCI161701.
Muter J, Lynch V, McCoy R, Brosens J Development. 2023; 150(10).
PMID: 37254877 PMC: 10281521. DOI: 10.1242/dev.201507.